Detection of multidrug resistance markers, P-glycoprotein and mdr1 mRNA, in human leukemia cells
Related Experiment Videos
T Tsuruo1, Y Sugimoto, H Hamada
1Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo.
Abstract:
We have examined the expression of P-glycoprotein in clinical leukemic cell samples by using a monoclonal antibody (MRK16) against P-glycoprotein. We found that leukemia cells isolated from 3 out of 6 patients with blast crisis of chronic myelogenous leukemia were reactive to MRK16. These 3 cell lines expressed high levels of mdr1 mRNA, which codes for P-glycoprotein. The present result indicates that the clinically refractory state of the tumor may be predicted in part by determining P-glycoprotein expression using the monoclonal antibody against P-glycoprotein, and the mdr1 probe.
Insights
P-glycoprotein expression in leukemia cells can predict treatment resistance. Detecting this protein using a monoclonal antibody (MRK16) and mdr1 mRNA levels may help forecast refractory cancer states.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- P-glycoprotein is a key efflux pump involved in multidrug resistance (MDR).
- Overexpression of P-glycoprotein in cancer cells can lead to therapeutic failure.
- Chronic myelogenous leukemia (CML) can develop resistance to standard treatments.
Purpose of the Study:
- To investigate P-glycoprotein expression in clinical samples of chronic myelogenous leukemia.
- To correlate P-glycoprotein levels with treatment refractoriness in CML patients.
Main Methods:
- Utilized a monoclonal antibody (MRK16) to detect P-glycoprotein expression.
- Analyzed mdr1 mRNA levels, which encode P-glycoprotein.
- Examined clinical leukemic cell samples from patients with CML in blast crisis.
Main Results:
- P-glycoprotein expression was detected in leukemia cells from 3 out of 6 patients with CML blast crisis.
- These reactive cell samples showed high levels of mdr1 mRNA.
- A correlation between P-glycoprotein expression and clinical refractoriness was observed.
Conclusions:
- P-glycoprotein expression, detectable by MRK16 antibody, is present in a subset of CML blast crisis patients.
- High mdr1 mRNA levels accompany P-glycoprotein overexpression in these resistant cells.
- Assessing P-glycoprotein and mdr1 mRNA may aid in predicting the refractory state of CML, guiding therapeutic strategies.